Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Rosty Raykov Sells 2,431 Shares

Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Rosty Raykov sold 2,431 shares of the company’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $6.13, for a total value of $14,902.03. Following the completion of the sale, the chief executive officer now directly owns 187,471 shares in the company, valued at $1,149,197.23. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Rosty Raykov also recently made the following trade(s):

• On Monday, June 3rd, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.76, for a total value of $16,433.56.
• On Wednesday, May 1st, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $9.11, for a total value of $22,146.41.
• On Friday, April 5th, Rosty Raykov sold 44,300 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.75, for a total value of $476,225.00.
• On Wednesday, April 3rd, Rosty Raykov sold 40,584 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.78, for a total value of $437,495.52.

Fennec Pharmaceuticals Trading Down 3.8 %

NASDAQ FENC opened at $6.03 on Wednesday. Fennec Pharmaceuticals Inc has a 12 month low of $5.99 and a 12 month high of $11.92. The stock has a market cap of $164.74 million, a P/E ratio of 201.00 and a beta of 0.29. The stock’s fifty day moving average price is $7.46 and its 200-day moving average price is $9.24. The company has a current ratio of 6.93, a quick ratio of 6.72 and a debt-to-equity ratio of 9.86.

Fennec Pharmaceuticals (NASDAQ:FENC) last announced its quarterly earnings results on Tuesday, May 14th. The company reported $0.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.08). The business had revenue of $25.38 million for the quarter, compared to the consensus estimate of $10.46 million. Fennec Pharmaceuticals had a net margin of 6.33% and a negative return on equity of 39.41%. During the same period in the previous year, the company earned ($0.23) earnings per share. As a group, equities analysts forecast that Fennec Pharmaceuticals Inc will post 0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its holdings in shares of Fennec Pharmaceuticals by 107.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock valued at $34,000 after purchasing an additional 1,578 shares in the last quarter. Hartford Financial Management Inc. lifted its holdings in shares of Fennec Pharmaceuticals by 4.4% during the fourth quarter. Hartford Financial Management Inc. now owns 47,348 shares of the company’s stock valued at $531,000 after purchasing an additional 2,000 shares in the last quarter. Eudaimonia Advisors LLC lifted its holdings in shares of Fennec Pharmaceuticals by 8.2% during the first quarter. Eudaimonia Advisors LLC now owns 35,359 shares of the company’s stock valued at $393,000 after purchasing an additional 2,673 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Fennec Pharmaceuticals by 67.7% during the first quarter. BNP Paribas Financial Markets now owns 32,769 shares of the company’s stock valued at $364,000 after purchasing an additional 13,223 shares in the last quarter. Finally, Jump Financial LLC bought a new position in shares of Fennec Pharmaceuticals during the fourth quarter valued at $158,000. 55.51% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on FENC. Craig Hallum cut their target price on Fennec Pharmaceuticals from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, May 15th. Wedbush reissued an “outperform” rating and issued a $16.00 target price on shares of Fennec Pharmaceuticals in a research note on Tuesday, May 14th. Finally, HC Wainwright cut their target price on Fennec Pharmaceuticals from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, May 15th.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.